CureVac N.V.

NASDAQ:CVAC   3:59:36 PM EDT
49.10
-0.03 (-0.06%)
Products, Regulatory

Curevac NV Says Initiates Phase 2A Clinical Trial Of COVID-19 Vaccine Candidate

Published: 09/29/2020 20:25 GMT
(CVAC) - Phase 2a Clinical Trial of Covid-19 Vaccine Candidate.
Study Conducted in Peru and Panama.
First Participant Has Been Dosed in a Phase 2a Clinical Trial of Its Covid-19 Vaccine Candidate, Cvncov.
Participants Will Receive Two Vaccinations at Intervals of 28 Days.
Phase 2a in Older Adults Are Expected Later in Q4 2020.
Curevac Plans to Initiate Global Phase 2b/3 Clinical Trial Enrolling Approximately 30,000 Participants in Q4 of 2020.
Curevac Plans to Initiate Global Phase 2b/3 Clinical Trial Enrolling Approximately 30,000 Participants in Q4 of 2020.
Trial Involves 690 Participants, Including Older Adults.